GeneDx Holdings (WGSWW) Accumulated Expenses (2020 - 2026)

GeneDx Holdings has disclosed Accumulated Expenses across 7 years of filings, most recently posting $24.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 75.81% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (up 75.81% YoY), while the FY2025 annual figure was $44.7 million, up 258.91% from the prior year.
• Accumulated Expenses slipped to $24.7 million in Q1 2026, from $44.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for WGSWW reached as high as $44.7 million in Q4 2025 and fell as low as $7.3 million in Q2 2024.
• The 5-year median for Accumulated Expenses is $18.5 million (2022), against an average of $20.0 million.
• Annual changes were most pronounced in 2024 — Accumulated Expenses sank 59.04% — and 2025, when it jumped 285.52%.
• A 5-year view of Accumulated Expenses shows it stood at $20.3 million in 2022, then sank by 40.05% to $12.2 million in 2023, then gained by 2.17% to $12.4 million in 2024, then jumped by 258.91% to $44.7 million in 2025, then tumbled by 44.79% to $24.7 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $24.7 million, $44.7 million, and $26.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.